Anne M. Komé

Anne M. Komé

Auto-generated profile, based on publicly available information

Anne M. Komé

Department of Pharmacy University of North Carolina Medical Center Chapel Hill North Carolina USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2025 in Diabetes Care
Verified
Journal Article
Closed access
AKAnne M. Komé
Anne M. Komé
MCMary M. Chandran
Mary M. Chandran
SLShelby S. Tungate Lopez
Shelby S. Tungate Lopez
JBJohn B. Buse
John B. Buse
KKKlara R. Klein
Klara R. Klein

30 December 2025 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
APAlejandro D. Perez
Alejandro D. Perez
RSRoss Joseph Simpson
Ross Joseph Simpson
AKAnne M. Komé
Anne M. Komé
SLShelby Tungate Lopez
Shelby Tungate Lopez

4 March 2025 in Diabetes Therapy
Verified
Journal Article
Open access
PDF file
AKAnne M. Komé
Anne M. Komé
AYAnita Yang
Anita Yang
PGPatrick Gee
Patrick Gee
KKKlara R. Klein
Klara R. Klein
People living with type 2 diabetes mellitus (T2DM) are at risk of developing diabetes-related complications such as chronic kidney disease (CKD). Screening for CKD is considered the standard of diabetes care, but less than half of people living with diabetes in the United States receive guideline-directed kidney disease testing. Despite recent pharmacologic advances for the treatment of this condition, insufficient screening delays both diagnosis and treatment of diabetes-related CKD and increases the risk of poor outcomes. The nonsteroidal mineralocorticoid receptor antagonist finerenone is an orally administered drug that, when taken with the maximum tolerated dose of a renin–angiotensin–aldosterone system inhibitor, can provide kidney and cardiovascular benefits for people living with T2DM-related CKD. Yet, uptake of this drug has been slow. Increasing awareness of finerenone may encourage its use in clinical practice. Diabetes educators are healthcare professionals (HCPs) with extensive diabetes care experience who encourage diabetes self-management and provide patients with education on the prevention of diabetes-related complications. Diabetes educators bridge knowledge and care gaps among other HCPs by facilitating communication between members of the care team and raising awareness on the importance of CKD prevention and screening. Additionally, diabetes educators reinforce the clinical evidence behind available treatments to promote adherence to guidelines. Here, the evidence for finerenone in T2DM-related CKD and the role of the diabetes educator from both patient and HCP perspectives are reviewed. Graphical abstract available for this article. Graphical Abstract

4 June 2026 in Obesity
Verified
Journal Article
Closed access
ALAbigail B. Lodrigues
Abigail B. Lodrigues
ARAlissa V. Russell
Alissa V. Russell
SLShelby Tungate Lopez
Shelby Tungate Lopez
AKAnne M. Komé
Anne M. Komé

8 April 2026 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
LHLily Huang
Lily Huang
ALAngela Lee
Angela Lee
DKDahye Kim
Dahye Kim
SLShelby Tungate Lopez
Shelby Tungate Lopez
AKAnne Komé
Anne Komé
AYAnita Yang
Anita Yang

18 September 2025 in JACCP: Journal of the American College of Clinical Pharmacy
Verified
Journal Article
Closed access
AKAnne M. Komé
Anne M. Komé
ABAmanda R. Boykin
Amanda R. Boykin
AJAlayah C. Johnson‐Jennings
Alayah C. Johnson‐Jennings
ACAndrea D. Coviello
Andrea D. Coviello